UK markets closed
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • FTSE 250

    20,961.31
    -334.92 (-1.57%)
     
  • AIM

    1,163.26
    -10.13 (-0.86%)
     
  • GBP/EUR

    1.1607
    +0.0010 (+0.09%)
     
  • GBP/USD

    1.3834
    -0.0060 (-0.43%)
     
  • BTC-GBP

    36,564.12
    +1,951.29 (+5.64%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • DOW

    31,496.30
    +572.16 (+1.85%)
     
  • CRUDE OIL

    66.28
    +2.45 (+3.84%)
     
  • GOLD FUTURES

    1,698.20
    -2.50 (-0.15%)
     
  • NIKKEI 225

    28,864.32
    -65.78 (-0.23%)
     
  • HANG SENG

    29,098.29
    -138.50 (-0.47%)
     
  • DAX

    13,920.69
    -135.65 (-0.97%)
     
  • CAC 40

    5,782.65
    -48.00 (-0.82%)
     

Annual General Meeting in ALK-Abelló A/S on 18 March 2021

ALK Abello
·1-min read

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): The Annual General Meeting of ALK-Abelló A/S will be held on Thursday 18 March 2021 at 4.00pm (CET) as a fully electronic Annual General Meeting. The agenda of the meeting including the complete proposals from the Board of Directors to the AGM is attached.

Shareholders who have registered their attendance can participate in the Annual General Meeting via VP’s VGM portal. The Annual General Meeting will also be webcast live at ALK’s website: https://ir.alk.net/agm.

ALK-Abelló A/S

For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Jeppe Ilkjær, mobile +45 3050 2014


About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,400 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Attachment